[ad_1]
Eli Lilly CEO David Ricks says his company has “one of the newest product portfolios” in the pharmaceutical industry through the acquisition of Prevail Therapeutics.
Eli Lilly’s antibody drug has been found to significantly reduce the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, the company said Thursday.
The drug is being evaluated in a Phase 3 trial involving 965 participants, led in part by the National Institute of Allergy and Infectious Diseases and the COVID-19 Prevention Network.
Stocks in this article
Monoclonal antibody therapy, called bamlanivimab, is currently approved by the FDA for the treatment of mild to moderate COVID-19 in adult and pediatric patients aged 12 years and older who are at high risk of progressing to Severe COVID. 19 and / or hospitalization. The FDA has stated that this includes patients who are 65 years of age or older or have certain chronic medical conditions.
ELI LILLY CEO: CORONAVIRUS TREATMENT MAY HELP ‘RELIEVE STRESS’
At the time of clearance, the FDA said the drug reduced COVID-19-related hospitalizations or emergency room visits in patients at high risk of disease progression within 28 days of treatment. It was not permitted for patients hospitalized due to COVID-19 or those requiring oxygen due to the virus. No benefit has been shown in patients hospitalized with the virus.
In the latest study, according to a press release released by Eli Lilly, at eight weeks of follow-up, there was a “significantly lower frequency of symptomatic COVID-19” in participants who received bamlanivimab compared to those who received the placebo.
AMAZON OFFERS ASSISTANCE TO BIDEN-HARRIS ON CLIMATE AND COVIDAS PROBLEMS
In a subgroup of nursing home residents, there was also a significantly lower frequency of symptomatic COVID-19 in those who received the drug compared to placebo.
Four participants who were in the placebo group died of COVID-19 during the trial period.
The company said the results reflected an up to 80% lower risk of contracting the virus.
“We are extremely pleased with these positive results, which have shown that bamlanivimab can help prevent COVID-19, dramatically reducing symptomatic illness among nursing home residents, some of the most vulnerable members of our society,” Daniel Skovronsky, MD, Ph.D., Lilly’s scientific director and president of Lilly’s research laboratories said in a press release.
CLICK HERE TO GET FOX BUSINESS ON THE ROAD
“These data provide important additional clinical evidence regarding the use of bamlanivimab to fight COVID-19 and strengthen our belief that monoclonal antibodies such as bamlanivimab can play a critical role in reversing the course of this pandemic,” a- he continued. “We are pleased that bamlanivimab is already available as a treatment for patients at high risk of progressing to severe COVID-19 illness or hospitalization, including those in nursing homes, and we look forward to working with regulators to explore the expansion of emergency use authorization to prevent the spread of COVID-19 in these facilities. “
[ad_2]
Source link